[en] Topical calcineurin inhibitors, also called topical immunomodulators or downregulators, represent an innovative class of non-steroidal anti-inflammatory agents. Pimecrolimus 1% cream (Elidel) is one representative drug available for the treatment of atopic dermatitis. Unlike topical steroids, this drug does not affect collagen synthesis and does not alter the dendritic cell functions and the barrier function of the skin.
Disciplines :
Dermatology
Author, co-author :
Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Language :
French
Title :
Comment je traite ... la dermatite atopique par le pimecrolimus topique (Elidel). Le paradigme émergent des inhibiteurs de la calcineurine.
Alternative titles :
[en] How I treat ... atopic dermatitis by topical pimecrolimus (Elidel). The emerging paradigm of calcineurin inhibitors.
Publication date :
2005
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Oranje AP, De Waard-Van Der Spek FB.- Atopic dermatitis: review 2000 to January 2001. Curr Opin Pediatr, 2002, 14, 410-413.
Flagothier C, Uhoda E, Goffin V, et al.- Biocénose cutanée, peptides antimicrobiens cutanés et antiseptiques. Dermatol Actual, 2004, 86, 22-24.
Goffin V, Piérard GE.- Corneosurfametry and the compromised atopic stratum corneum. Arch Dermatol Res, 1996, 288, 489-491.
Kondo H, Ichikawa Y, Imokawa G.- Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol, 1998, 28, 769-779.
Taieb A.- Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis, 1999, 41, 177-180.
Macheleidt O, Kaiser HW, Sandhoff K.- Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol, 2002, 119, 166-173.
Galli E, Cicconi R, Rossi P, et al.- Atopic dermatitis: molecular mechanism, clinical aspects and new therapeutical approaches. Curr Mol Med, 2003, 3, 127-138.
Reitamo S, Remitz A, Kyllonen H, Saarikko J.- Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol, 2002, 3, 381-388.
Piérard GE, Piérard-Franchimont C.- Skin immune downregulators: from bench to bedside. Curr Top Pharmacol, 2003, 7, 109-116.
Tomi SN, Luger TA.- The treatment of atopic dermatitis with topical immunomodulators. Clin Dermatol, 2003, 21, 215-224.
Iskedjian M, Piwko C, Shear H, et al.- Topical calcineurin inhibitors in the treatment of atopic dermatitis. A meta-analysis of current evidence. Am J Clin Dermatol, 2004, 5, 267-279.
Piérard GE, Piérard-Franchimont C, Paquet P- Le tacrolimus topique (Protopic®). Rev Med Liège, 2002, 57, 552-555.
Grassberger M, Baumruker T, Enz A, et al.- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol, 1999, 141, 264-273.
Wellington K, Jarvis B.- Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs, 2002, 62, 817-840.
Graham-Brown RA, Grassberger M.- Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract, 2003, 57, 319-327.
Quatresooz P, Fumal I, Piérard-Franchimont C, Piérard GE.- Le pimecrolimus topique (Elidel®). Rev Med Liège, 2003, 58, 168-171.
Kalthoff FS, Chung J, Musser P, et al.- Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol, 2003, 133, 350-359.
Billich A, Aschauer H, Aszodi A, et al.- Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm, 2004, 269, 29-35.
Van Leent EJM, Ebelin M-E, Burtin P, et al.- Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology, 2002, 204, 63-68.
Allen BR, Lakhanpaul M, Morris A, et al.- Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child, 2003, 88, 969-973.
Kempers S, Boguniewicz M, Carter E, et al.- A randomized, investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pédiatric patients with moderate atopic dermatitis. J Am Acad Dermatol, 2004, 51, 515-525.
Eichenfield LF, Lucky AW, Boguniewicz M, et al.-Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol, 2002, 46, 495-504.
Kapp A, Papp K, Bingham A, et al.- Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol, 2002, 110, 277-284.
Meurer M, Fölster-Holst R, Wozel G, et al.- Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. CASM-DE-01 Study Group. Dermatology, 2002, 205, 271-277.
Wellington K, Jarvis B.- Spotlight on topical pimecrolimus in atopic dermatitis. Am J Clin Dermatol, 2002, 3, 435-438.
Ho VC, Gupta A, Kaufmann R, et al.- Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr, 2003, 142, 155-162.
Weinberg JM, Bowermann JG, Brown SM, et al.- Atopic dermatitis: a new treatment paradigm using pimecrolimus. J Drugs Dermatol, 2003, 2, 131-140.
Hanifin JM, Cooper KD, Ho VC, et al.- Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Adminisrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol, 2004, 50, 391-404.
Luger TA, Lahfa M, Fölster-Holst R, et al.- Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroid in adults with moderate to severe atopic dermatitis. J Dermatol Treat, 2004, 15, 169-178.
Meurer M, Fartasch M, Albrecht G, et al.- Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology, 2004, 208, 365-372.
Papp K, Staab D, Harper J, et al.- Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int J Dermatol, 2004, 43, 978-983.
Wellington K, Noble S.- Pimecrolimus. A review of its use in atopic dermatitis. Am J Clin Dermatol, 2004, 5, 479-495.
Wolff K, Stuetz A.- Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother, 2004, 5, 643-655.
Letawe C, Piérard-Franchimont C, Piérard GE.- Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis. Eur J Clin Pharmacol, 1996, 51, 253-258.
